Blow for UK drugs sector as Merck scraps £1bn expansion

Merck, known as MSD in Europe, has scrapped a planned £1 billion expansion of its UK operations, dealing a blow to the country's pharmaceutical industry. The company cited a lack of investment in the life sciences sector as the primary reason for the decision. The planned expansion was set to create hundreds of new jobs and solidify the UK's position as a hub for pharmaceutical research and development. However, Merck's decision reflects the broader challenges facing the industry, including the impact of Brexit and the ongoing economic uncertainty. The scrapping of the investment plan is a significant setback for the UK government's efforts to maintain the country's competitiveness in the life sciences sector, which is a crucial part of the economy. Industry experts have warned that the decision could have wider implications for the sector and the broader economy, as it may discourage other companies from investing in the UK.